ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

Rhea-AI Summary

ZyVersa Therapeutics (NASDAQ: ZVSA) announces CEO Stephen C. Glover's attendance at JPM's 43rd Annual Healthcare Conference 2025 in San Francisco from January 13-16, 2025. The company is developing two key drug candidates: IC 100, an Inflammasome ASC Inhibitor targeting obesity with metabolic complications, and VAR 200, a Cholesterol Efflux Mediator for kidney diseases.

VAR 200 is expected to begin Phase 2a clinical trials for diabetic kidney disease in Q1-2025. The company's CEO will be available for one-on-one meetings to discuss ZyVersa's technology, pipeline assets, and development milestones with industry strategics and investors during the conference.

• ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies.

- Inflammasome ASC Inhibitor IC 100 designed to attenuate initiation and perpetuation of disease-causing inflammation; lead indication: obesity with metabolic complications (e.g., cardiovascular disease).

- Cholesterol Efflux Mediator™ VAR 200 designed to mediate removal of renal lipids and cholesterol that lead to kidney damage and disease; phase 2a clinical trial in diabetic kidney disease expected to begin Q1-2025.

• Mr. Glover welcomes one-on-one meetings to discuss ZyVersa’s technology, pipeline assets, and key development milestones.

WESTON, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with inflammatory and renal diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will attend JPM’s 43rd Annual Healthcare Conference 2025 being held January 13 – 16, 2025 in San Francisco.

“We look forward to meeting with industry strategics and investors during JPM 2025 to discuss the value building opportunities expected with our highly differentiated Inflammasome ASC Inhibitor IC 100 and Cholesterol Efflux Mediator^TM VAR 200, said Stephen Glover.” To meet with Mr. Glover, please contact Zach Glover at zglover@zyversa.com.

To learn more about ZyVersa and its innovative and differentiated product pipeline, please visit www.zyversa.com.

About ZyVersa Therapeutics, Inc.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux Mediator^TM VAR 200. The lead indication for IC 100 is obesity with metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS). Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $100 billion. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc. (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.

New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this presentation. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by applicable law.

Corporate, IR, and Media Contact
Karen Cashmere
Chief Commercial Officer
kcashmere@zyversa.com
786-251-9641                

                

FAQ

When will ZyVersa (ZVSA) begin Phase 2a clinical trials for VAR 200?

ZyVersa plans to begin Phase 2a clinical trials for VAR 200 in diabetic kidney disease in Q1-2025.

What are the two main drug candidates in ZyVersa's (ZVSA) pipeline?

ZyVersa's pipeline includes IC 100, an Inflammasome ASC Inhibitor for obesity with metabolic complications, and VAR 200, a Cholesterol Efflux Mediator for kidney diseases.

What is the primary indication for ZyVersa's (ZVSA) IC 100 drug candidate?

IC 100's lead indication is obesity with metabolic complications, such as cardiovascular disease.

When and where is ZyVersa (ZVSA) presenting at the JPM Healthcare Conference 2025?

ZyVersa will attend JPM's 43rd Annual Healthcare Conference from January 13-16, 2025, in San Francisco.

What is the therapeutic target of ZyVersa's (ZVSA) VAR 200 drug?

VAR 200 is designed to mediate the removal of renal lipids and cholesterol that lead to kidney damage and disease.